title: Female adolescent exposure to cannabinoids causes transgenerational effects on morphine sensitization in female offspring in the absence of in utero exposure.
abstract: Female adolescent marijuana use is increasing, yet the effect on future offspring is unknown. Here, adolescent female Sprague Dawley rats (postnatal-day 30; PN30) were given subcutaneous (s.c.) injections with the cannabinoid agonist WIN-55,212 (WIN) or its vehicle (VEH) for three consecutive days using a twice-daily, increasing dosage regimen (1 mg/kg day 1; 2 mg/kg day 2; 4 mg/kg day 3). As adults (PN60), females were mated with drug-naïve males. Their adult female offspring (VEH-F1 or WIN-F1) were tested for behavioral sensitization by administering morphine (0 or 7.5 mg/kg s.c.) every other day for a total of five administrations. Following five days of abstinence, all animals received a morphine challenge (7.5 mg/kg s.c.) and locomotor activity was monitored. At completion of behavioral testing, mu opioid receptor (OPRM1), FosB, cFos, and dopamine receptor mRNA expression was measured in the nucleus accumbens as well as OPRM1 and corticotropin-releasing hormone mRNA in the paraventricular nucleus. In addition, plasma corticosterone levels were examined. On the day of challenge, morphine-pretreated WIN-F1 animals demonstrated a significantly enhanced response to morphine compared to morphine-pretreated VEH-F1 animals. Also following the morphine challenge, significantly higher levels of OPRM1 in the nucleus accumbens were observed in WIN-F1 animals. Together, these findings demonstrate transgenerational effects of adolescent exposure to cannabinoids in the absence of any in utero exposure.
authors.affiliation: Department of Biomedical Sciences, Tufts University, Grafton, USA.
authors.forename: Fair M
authors.initials: FM
authors.lastname: Vassoler
authors.forename: Nicole L
authors.initials: NL
authors.lastname: Johnson
authors.forename: Elizabeth M
authors.initials: EM
authors.lastname: Byrnes
mesh_terms: D000818:Animals; D048588:Benzoxazines / Q000494:pharmacology*; D002186:Cannabinoids / Q000494:pharmacology*; D059333:Central Nervous System Sensitization / Q000187:drug effects* / Q000235:genetics*; D003345:Corticosterone / Q000097:blood; D003346:Corticotropin-Releasing Hormone / Q000235:genetics; D044127:Epigenesis, Genetic / Q000235:genetics; D005260:Female; D015870:Gene Expression / Q000187:drug effects; D016762:Genes, fos / Q000235:genetics; D009020:Morphine / Q000494:pharmacology*; D009025:Morpholines / Q000494:pharmacology*; D009043:Motor Activity / Q000187:drug effects; D009281:Naphthalenes / Q000494:pharmacology*; D009714:Nucleus Accumbens / Q000378:metabolism; D010286:Paraventricular Hypothalamic Nucleus / Q000378:metabolism; D016760:Proto-Oncogene Proteins c-fos / Q000235:genetics; D019655:Quantitative Trait, Heritable; D051381:Rats; D011954:Receptors, Dopamine / Q000235:genetics; D017450:Receptors, Opioid, mu / Q000235:genetics; D014599:Uterus
chemical_list: D048588:Benzoxazines; D002186:Cannabinoids; C483820:Fosb protein, rat; D009025:Morpholines; D009281:Naphthalenes; D016760:Proto-Oncogene Proteins c-fos; D011954:Receptors, Dopamine; D017450:Receptors, Opioid, mu; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; D009020:Morphine; D003346:Corticotropin-Releasing Hormone; D003345:Corticosterone
keywords: Cannabinoids; adolescence; morphine; sensitization; transgenerational
references.citation: J Psychopharmacol. 2012 Oct;26(10):1348-54
references.pmid: 22516667
references.citation: Front Psychiatry. 2011 Jun 06;2:29
references.pmid: 21713113
references.citation: Proc Natl Acad Sci U S A. 2010 Nov 23;107(47):20535-40
references.pmid: 21059913
references.citation: Biol Psychiatry. 2001 Jan 15;49(2):81-96
references.pmid: 11164755
references.citation: Brain Res. 1992 Aug 14;588(1):104-14
references.pmid: 1327405
references.citation: J Psychopharmacol. 2012 Jan;26(1):150-63
references.pmid: 21693551
references.citation: Brain Res. 1992 Dec 11;598(1-2):343-8
references.pmid: 1486498
references.citation: Environ Health Perspect. 2000 Jun;108 Suppl 3:511-33
references.pmid: 10852851
references.citation: Neuropsychopharmacology. 2007 Mar;32(3):607-15
references.pmid: 16823391
references.citation: J Neurochem. 2003 Mar;84(5):930-8
references.pmid: 12603818
references.citation: Brain Res. 2008 Mar 14;1199:91-9
references.pmid: 18279841
references.citation: Neurosci Biobehav Rev. 2000 Jun;24(4):417-63
references.pmid: 10817843
references.citation: Neurosci Biobehav Rev. 2011 Aug;35(8):1740-51
references.pmid: 20869396
references.citation: Behav Brain Res. 2009 Jul 19;201(1):128-36
references.pmid: 19428626
references.citation: Chang Gung Med J. 2009 Mar-Apr;32(2):148-54
references.pmid: 19403004
references.citation: J Psychopharmacol. 2012 Jan;26(1):164-76
references.pmid: 21669929
references.citation: Addict Biol. 2008 Jun;13(2):253-63
references.pmid: 18482434
references.citation: Neurosci Biobehav Rev. 2006;30(5):680-95
references.pmid: 16574226
references.citation: Brain Res. 1993 May 21;611(2):352-6
references.pmid: 8334527
references.citation: Neurosci Biobehav Rev. 2003 Jan-Mar;27(1-2):3-18
references.pmid: 12732219
references.citation: Life Sci. 2013 Mar 19;92(8-9):476-81
references.pmid: 22728714
references.citation: J Chem Neuroanat. 1995 May;8(4):283-305
references.pmid: 7669273
references.citation: Neurochem Res. 2010 Jun;35(6):851-67
references.pmid: 20012687
references.citation: Front Biosci (Landmark Ed). 2011 Jan 01;16:498-516
references.pmid: 21196184
references.citation: Exp Clin Psychopharmacol. 2008 Oct;16(5):376-85
references.pmid: 18837634
references.citation: Addict Biol. 2013 Nov;18(6):1013-23
references.pmid: 22994937
references.citation: Neuropsychopharmacology. 2013 Jan;38(1):220-36
references.pmid: 22781843
references.citation: Annu Rev Pharmacol Toxicol. 1993;33:353-82
references.pmid: 8494344
references.citation: Stress. 2011 Jul;14(4):348-56
references.pmid: 21663536
references.citation: Philos Trans R Soc Lond B Biol Sci. 2013 Jan 5;368(1609):20110327
references.pmid: 23166391
references.citation: Biol Psychiatry. 2007 Feb 15;61(4):554-63
references.pmid: 16876136
references.citation: Behav Brain Res. 2011 Jun 1;219(2):265-72
references.pmid: 21262268
references.citation: Eur J Neurosci. 2003 Mar;17(5):1067-72
references.pmid: 12653982
references.citation: Domest Anim Endocrinol. 1992 Jul;9(3):225-32
references.pmid: 1458876
references.citation: Biol Psychiatry. 2004 Jul 15;56(2):86-94
references.pmid: 15231440
references.citation: PLoS One. 2011;6(8):e23574
references.pmid: 21886798
references.citation: Neuropsychopharmacology. 2010 Nov;35(12):2450-61
references.pmid: 20720536
references.citation: Prog Brain Res. 2001;133:287-302
references.pmid: 11589138
references.citation: Brain Res. 1992 Jul 3;584(1-2):309-13
references.pmid: 1515947
references.citation: Mol Cell Endocrinol. 2012 May 6;354(1-2):3-8
references.pmid: 22020198
references.citation: Prog Biophys Mol Biol. 2013 Dec;113(3):439-46
references.pmid: 23257323
references.citation: Psychopharmacology (Berl). 2000 Aug;151(2-3):99-120
references.pmid: 10972458
references.citation: Aust N Z J Psychiatry. 2008 May;42(5):357-68
references.pmid: 18473254
references.citation: Brain Res. 1988 Aug 9;457(2):287-94
references.pmid: 3219557